Atea Pharmaceuticals Inc (AVIR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Atea Pharmaceuticals Inc (AVIR) has a cash flow conversion efficiency ratio of -0.198x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-46.39 Million) by net assets ($233.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Atea Pharmaceuticals Inc to measure how much of total assets are equity-financed.
Atea Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Atea Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check AVIR cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Atea Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Atea Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sky Harbour Group Corporation
NYSE:SKYH
|
-0.024x |
|
Ngx Energy International Corp
V:GASX
|
-0.013x |
|
Chen Ke Ming Food Manufacturing Co Ltd
SHE:002661
|
0.076x |
|
Zbom Cabinets Co Ltd
SHG:603801
|
0.089x |
|
Enento Group Plc
HE:ENENTO
|
0.057x |
|
Dave & Buster’s Entertainment
NASDAQ:PLAY
|
1.129x |
|
Enjoyor
SHE:300020
|
0.013x |
|
NH SPAC 8
KQ:225570
|
-0.014x |
Annual Cash Flow Conversion Efficiency for Atea Pharmaceuticals Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Atea Pharmaceuticals Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Atea Pharmaceuticals Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $275.43 Million | $-132.03 Million | -0.479x | -55.26% |
| 2024-12-31 | $438.87 Million | $-135.50 Million | -0.309x | -100.73% |
| 2023-12-31 | $555.19 Million | $-85.39 Million | -0.154x | +18.56% |
| 2022-12-31 | $640.57 Million | $-120.98 Million | -0.189x | -54.14% |
| 2021-12-31 | $710.08 Million | $-87.00 Million | -0.123x | -122.62% |
| 2020-12-31 | $547.80 Million | $296.73 Million | 0.542x | +109.55% |
| 2019-12-31 | $-49.57 Million | $-12.81 Million | 0.258x | +18.20% |
| 2018-12-31 | $-36.16 Million | $-7.91 Million | 0.219x | -- |
About Atea Pharmaceuticals Inc
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company … Read more